CHAMPIONS ONCOLOGY, INC. (CSBR) Operating Margin
- Operating margin · 12 months: Value -1.68%; Formula and calculation Operating income / revenue. Period ending 2026-07-31..
Operating margin
Overview →Financial period ending 2026-07-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -1.68% | Operating income / revenue. Period ending 2026-07-31. $-1.02M ÷ $60.66M × 100 ≈ -1.68% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -1.02M USD | Operating Income (Loss) |
| Revenue | 60.66M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 30.44M USD | Cost of Goods and Services Sold |
| Research and development | 9.35M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-07-31 | $-1.02M | $60.66M | $30.44M | $9.35M | (m) | -1.68% |
| 2026-04-30 | $-1.14M | $59.42M | $30.90M | $9.08M | (m) | -1.92% |
| 2026-01-31 | $-2.63M | $57.95M | $31.36M | $8.93M | (m) | -4.53% |
| 2025-10-31 | $2.15M | $58.42M | $29.15M | $8.38M | (m) | 3.68% |
| 2025-07-31 | $2.70M | $56.88M | $29.31M | $7.45M | (m) | 4.74% |
| 2025-04-30 | $4.55M | $56.94M | $28.39M | $6.83M | (m) | 8.00% |
| 2025-01-31 | $6.29M | $58.59M | $28.37M | $6.91M | (m) | 10.73% |
| 2024-10-31 | $-788.00K | $53.57M | $29.60M | $7.38M | (m) | -1.47% |
| 2024-07-31 | $-3.48M | $51.66M | $28.79M | $8.21M | (m) | -6.73% |
| 2024-04-30 | $-7.36M | $50.16M | $29.40M | $9.54M | (m) | -14.67% |
| 2024-01-31 | $-9.61M | $49.22M | $29.49M | $10.35M | (m) | -19.51% |
| 2023-10-31 | $-9.49M | $49.98M | $29.34M | $11.36M | (m) | -18.98% |
| 2023-07-31 | $-7.52M | $52.69M | $30.16M | $11.45M | (m) | -14.28% |
| 2023-04-30 | $-5.26M | $53.87M | $29.53M | $11.54M | (m) | -9.76% |
| 2023-01-31 | $-3.05M | $53.68M | $28.41M | $11.28M | (m) | -5.67% |
| 2022-10-31 | $242.00K | $54.10M | $27.12M | $10.26M | (m) | 0.45% |
| 2022-07-31 | $498.00K | $51.60M | $25.29M | $9.96M | (m) | 0.97% |
| 2022-04-30 | $607.00K | $49.11M | $23.63M | $9.37M | (m) | 1.24% |
| 2022-01-31 | $270.00K | $46.80M | $23.25M | $8.85M | (m) | 0.58% |
| 2021-10-31 | $423.00K | $44.41M | $21.47M | $8.55M | (m) | 0.95% |
| 2021-07-31 | $167.00K | $42.75M | $21.51M | $7.90M | (m) | 0.39% |
| 2021-04-30 | $366.00K | $41.04M | $21.45M | $7.20M | (m) | 0.89% |
| 2021-01-31 | $-1.12M | $39.22M | (m) | $6.94M | (m) | -2.85% |
| 2020-10-31 | $-1.45M | $37.42M | (m) | $6.46M | (m) | -3.87% |
| 2020-07-31 | $-1.17M | $34.93M | (m) | $6.15M | (m) | -3.33% |
| 2020-04-30 | $-1.80M | $32.12M | (m) | $5.85M | (m) | -5.61% |
| 2020-01-31 | $-7.00K | $31.09M | (m) | $5.28M | (m) | -0.02% |
| 2019-10-31 | $-810.00K | (m) | (m) | $5.16M | (m) | (m) |
| 2019-07-31 | $-825.00K | (m) | (m) | $5.01M | (m) | (m) |
| 2019-04-30 | $270.00K | $27.07M | (m) | $4.80M | (m) | 1.00% |
| 2019-01-31 | $-213.00K | (m) | (m) | $4.64M | (m) | (m) |
| 2018-10-31 | $92.00K | (m) | (m) | $4.45M | (m) | (m) |
| 2018-07-31 | $-254.00K | (m) | (m) | $4.37M | (m) | (m) |
| 2018-04-30 | $-1.35M | (m) | (m) | $4.40M | (m) | (m) |
| 2018-01-31 | $-3.14M | (m) | (m) | $4.38M | (m) | (m) |
| 2017-10-31 | $-4.48M | (m) | (m) | $4.31M | (m) | (m) |
| 2017-07-31 | $-4.91M | (m) | (m) | $4.20M | (m) | (m) |
| 2017-04-30 | $-6.81M | (m) | (m) | $4.29M | (m) | (m) |
| 2017-01-31 | $-6.97M | (m) | (m) | $4.39M | (m) | (m) |
| 2016-10-31 | $-7.94M | (m) | (m) | $4.39M | (m) | (m) |
| 2016-07-31 | $-9.94M | (m) | (m) | $4.30M | (m) | (m) |
| 2016-04-30 | $-10.32M | (m) | (m) | $4.19M | (m) | (m) |
| 2016-01-31 | $-10.17M | (m) | (m) | $4.11M | (m) | (m) |
| 2015-10-31 | $-11.24M | (m) | (m) | $4.20M | (m) | (m) |
| 2015-07-31 | $-12.41M | (m) | (m) | $4.52M | (m) | (m) |
| 2015-04-30 | $-13.24M | (m) | (m) | $4.84M | (m) | (m) |
| 2015-01-31 | $-13.21M | (m) | (m) | $4.41M | (m) | (m) |
| 2014-10-31 | $-11.18M | (m) | (m) | $3.85M | (m) | (m) |
| 2014-07-31 | $-9.22M | (m) | (m) | $3.29M | (m) | (m) |
| 2014-04-30 | $-6.26M | (m) | (m) | $2.27M | (m) | (m) |
| 2014-01-31 | $-5.87M | (m) | (m) | $2.12M | (m) | (m) |
| 2013-10-31 | $-5.18M | (m) | (m) | $2.18M | (m) | (m) |
| 2013-07-31 | $-5.39M | (m) | (m) | $1.94M | (m) | (m) |
| 2013-04-30 | $-6.22M | (m) | (m) | $1.92M | (m) | (m) |
| 2013-01-31 | $-6.84M | (m) | (m) | $1.79M | (m) | (m) |
| 2012-10-31 | $-7.90M | (m) | (m) | $2.14M | (m) | (m) |
| 2012-07-31 | $-8.45M | (m) | (m) | $2.78M | (m) | (m) |
| 2012-04-30 | $-9.06M | (m) | (m) | $2.94M | (m) | (m) |
| 2012-01-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-10-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-07-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-04-30 | $-5.24M | (m) | (m) | $2.91M | (m) | (m) |
| 2011-01-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-10-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-07-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |